Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
YieldBasis (YB) 24-hour volatility reaches 40.5%: Trading volume surges 173% driving price rebound

YieldBasis (YB) 24-hour volatility reaches 40.5%: Trading volume surges 173% driving price rebound

Bitget PulseBitget Pulse2026/04/18 05:20
Show original
By:Bitget Pulse

Volatility Brief

In the past 24 hours, YB's price rebounded from a low of $0.1206 to a high of $0.1694, currently quoted at $0.1687, with a price fluctuation amplitude of 40.5%. Trading volume surged by 173.7% to $26.85 million, significantly higher than the previous day. Net outflows from CEX amounted to about $212,000, while DEX saw a slight net inflow of $4,025.

Brief Analysis of the Cause of the Volatility

- Trading volume spiking by 173.7% to $26.85 million was mainly driven by speculative buying, with no official announcements or major news events.

- Influenced by the Q1 earnings report released one day ago, which showed the protocol gained $12 million in fees from BTC volatility and TVL reached $196 million.

- No significant whale activity or on-chain anomalies observed.

Market View and Outlook

Main sentiment in the X community is short-term bullish, with active trading signals and bulls entering from $0.1164, hitting multiple TPs at $0.138 and beyond with profits exceeding 900%; some views believe the move is pure momentum-driven with volume up +419%, but warn of potential sell pressure from upcoming token unlocks and risks of a rapid pullback, suggesting to wait for support confirmation.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23